Literature DB >> 24786708

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes.

Mark E Molitch1, Amanda I Adler2, Allan Flyvbjerg3, Robert G Nelson4, Wing-Yee So5, Christoph Wanner6, Bertram L Kasiske7, David C Wheeler8, Dick de Zeeuw9, Carl E Mogensen10.   

Abstract

The incidence and prevalence of diabetes mellitus (DM) continue to grow markedly throughout the world, due primarily to the increase in type 2 DM (T2DM). Although improvements in DM and hypertension management have reduced the proportion of diabetic individuals who develop chronic kidney disease (CKD) and progress to end-stage renal disease (ESRD), the sheer increase in people developing DM will have a major impact on dialysis and transplant needs. This KDIGO conference addressed a number of controversial areas in the management of DM patients with CKD, including aspects of screening for CKD with measurements of albuminuria and estimated glomerular filtration rate (eGFR); defining treatment outcomes; glycemic management in both those developing CKD and those with ESRD; hypertension goals and management, including blockers of the renin-angiotensin-aldosterone system; and lipid management.

Entities:  

Mesh:

Year:  2014        PMID: 24786708      PMCID: PMC4214898          DOI: 10.1038/ki.2014.128

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  105 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

Authors:  Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

Authors:  Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

5.  UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.

Authors:  A J Hayes; J Leal; A M Gray; R R Holman; P M Clarke
Journal:  Diabetologia       Date:  2013-06-22       Impact factor: 10.122

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.

Authors:  Hallvard Holdaas; Bengt Fellström; Alan G Jardine; Ingar Holme; Gudrun Nyberg; Per Fauchald; Carola Grönhagen-Riska; Søren Madsen; Hans-Hellmut Neumayer; Edward Cole; Bart Maes; Patrice Ambühl; Anders G Olsson; Anders Hartmann; Dag O Solbu; Terje R Pedersen
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

9.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

10.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller
Journal:  Am J Kidney Dis       Date:  2009-06-21       Impact factor: 8.860

View more
  79 in total

1.  Niclosamide ethanolamine improves diabetes and diabetic kidney disease in mice.

Authors:  Pengxun Han; Mumin Shao; Lan Guo; Wenjing Wang; Gaofeng Song; Xuewen Yu; Chunlei Zhang; Na Ge; Tiegang Yi; Shunmin Li; Heng Du; Huili Sun
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

Review 2.  [Diabetic kidney disease - Update 2016].

Authors:  Harald Sourij; Roland Edlinger; Friedrich Prischl; Martin Auinger; Alexandra Kautzky-Willer; Marcus D Säemann; Rudolf Prager; Martin Clodi; Guntram Schernthaner; Gert Mayer; Rainer Oberbauer; Alexander R Rosenkranz
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

3.  Diagnostic value of quantitative contrast-enhanced ultrasound (CEUS) for early detection of renal hyperperfusion in diabetic kidney disease.

Authors:  Ling Wang; Jian Wu; Jia-Fen Cheng; Xin-Ying Liu; Fang Ma; Le-Hang Guo; Jun-Mei Xu; Tianfu Wu; Chandra Mohan; Ai Peng; Hui-Xiong Xu; Ya-Xiang Song
Journal:  J Nephrol       Date:  2015-02-25       Impact factor: 3.902

4.  Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Authors:  Tamara Isakova; Timothy E Craven; Jungwha Lee; Julia J Scialla; Huiliang Xie; Patricia Wahl; Santica M Marcovina; Robert P Byington; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-24       Impact factor: 8.237

Review 5.  Diet and Diabetic Kidney Disease: Plant Versus Animal Protein.

Authors:  Ranjani N Moorthi; Colby J Vorland; Kathleen M Hill Gallant
Journal:  Curr Diab Rep       Date:  2017-03       Impact factor: 4.810

6.  Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.

Authors:  Luminita Voroneanu; Dimitrie Siriopol; Raluca Dumea; Silvia Badarau; Mehmet Kanbay; Baris Afsar; Cristina Gavrilovici; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2017-09-25       Impact factor: 2.370

Review 7.  Store-operated calcium entry and diabetic complications.

Authors:  Sarika Chaudhari; Rong Ma
Journal:  Exp Biol Med (Maywood)       Date:  2015-10-14

8.  Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014.

Authors:  Maryam Afkarian; Leila R Zelnick; Yoshio N Hall; Patrick J Heagerty; Katherine Tuttle; Noel S Weiss; Ian H de Boer
Journal:  JAMA       Date:  2016-08-09       Impact factor: 56.272

9.  Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial.

Authors:  Benjamin M Scirica; Ofri Mosenzon; Deepak L Bhatt; Jacob A Udell; Ph Gabriel Steg; Darren K McGuire; KyungAh Im; Estella Kanevsky; Christina Stahre; Mikaela Sjöstrand; Itamar Raz; Eugene Braunwald
Journal:  JAMA Cardiol       Date:  2018-02-01       Impact factor: 14.676

10.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study).

Authors:  Takashi Wada; Tatsuo Hosoya; Daisuke Honda; Ryusuke Sakamoto; Kazutaka Narita; Tomomitsu Sasaki; Daisuke Okui; Kenjiro Kimura
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.